Ignite Creation Date:
2025-12-24 @ 7:25 PM
Ignite Modification Date:
2026-02-25 @ 8:59 PM
Study NCT ID:
NCT02807103
Status:
COMPLETED
Last Update Posted:
2021-04-14
First Post:
2016-05-20
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Rituximab in Eosinophilic Granulomatosis With Polyangiitis
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D015267', 'term': 'Churg-Strauss Syndrome'}], 'ancestors': [{'id': 'D056648', 'term': 'Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis'}, {'id': 'D056647', 'term': 'Systemic Vasculitis'}, {'id': 'D014657', 'term': 'Vasculitis'}, {'id': 'D014652', 'term': 'Vascular Diseases'}, {'id': 'D002318', 'term': 'Cardiovascular Diseases'}, {'id': 'D006099', 'term': 'Granuloma'}, {'id': 'D008232', 'term': 'Lymphoproliferative Disorders'}, {'id': 'D008206', 'term': 'Lymphatic Diseases'}, {'id': 'D006425', 'term': 'Hemic and Lymphatic Diseases'}, {'id': 'D017445', 'term': 'Skin Diseases, Vascular'}, {'id': 'D012871', 'term': 'Skin Diseases'}, {'id': 'D017437', 'term': 'Skin and Connective Tissue Diseases'}, {'id': 'D001327', 'term': 'Autoimmune Diseases'}, {'id': 'D007154', 'term': 'Immune System Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D000069283', 'term': 'Rituximab'}, {'id': 'D012965', 'term': 'Sodium Chloride'}, {'id': 'D003520', 'term': 'Cyclophosphamide'}], 'ancestors': [{'id': 'D058846', 'term': 'Antibodies, Monoclonal, Murine-Derived'}, {'id': 'D000911', 'term': 'Antibodies, Monoclonal'}, {'id': 'D000906', 'term': 'Antibodies'}, {'id': 'D007136', 'term': 'Immunoglobulins'}, {'id': 'D007162', 'term': 'Immunoproteins'}, {'id': 'D001798', 'term': 'Blood Proteins'}, {'id': 'D011506', 'term': 'Proteins'}, {'id': 'D000602', 'term': 'Amino Acids, Peptides, and Proteins'}, {'id': 'D012712', 'term': 'Serum Globulins'}, {'id': 'D005916', 'term': 'Globulins'}, {'id': 'D002712', 'term': 'Chlorides'}, {'id': 'D006851', 'term': 'Hydrochloric Acid'}, {'id': 'D017606', 'term': 'Chlorine Compounds'}, {'id': 'D007287', 'term': 'Inorganic Chemicals'}, {'id': 'D017670', 'term': 'Sodium Compounds'}, {'id': 'D010752', 'term': 'Phosphoramide Mustards'}, {'id': 'D009588', 'term': 'Nitrogen Mustard Compounds'}, {'id': 'D009150', 'term': 'Mustard Compounds'}, {'id': 'D006846', 'term': 'Hydrocarbons, Halogenated'}, {'id': 'D006838', 'term': 'Hydrocarbons'}, {'id': 'D009930', 'term': 'Organic Chemicals'}, {'id': 'D063088', 'term': 'Phosphoramides'}, {'id': 'D009943', 'term': 'Organophosphorus Compounds'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE3'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'QUADRUPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 107}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2016-12-05', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2021-04', 'completionDateStruct': {'date': '2020-10-21', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2021-04-13', 'studyFirstSubmitDate': '2016-05-20', 'studyFirstSubmitQcDate': '2016-06-16', 'lastUpdatePostDateStruct': {'date': '2021-04-14', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2016-06-21', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2020-10-21', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'The percentage of patients who obtained a BVAS=0 and prednisone dose ≤7.5 mg/day at day 180.', 'timeFrame': '180 days'}], 'secondaryOutcomes': [{'measure': 'Number of adverse events', 'timeFrame': '180 days', 'description': 'expressed as adverse events according to the CTCAE toxicity grading system per patient-year for the following adverse events combined: death (all causes), grade 2 or higher leukopenia or thrombocytopenia, grade 3 or higher infections, hemorrhagic cystitis, malignancies, venous thromboembolic events, hospitalization resulting either from the disease or from a complication due to the study treatment, infusion reactions (within 24 hours of infusion) that result in the cessation of further infusions'}, {'measure': 'Number of adverse events', 'timeFrame': '360 days', 'description': 'expressed as adverse events according to the CTCAE toxicity grading system per patient-year for the following adverse events combined: death (all causes), grade 2 or higher leukopenia or thrombocytopenia, grade 3 or higher infections, hemorrhagic cystitis, malignancies, venous thromboembolic events, hospitalization resulting either from the disease or from a complication due to the study treatment, infusion reactions (within 24 hours of infusion) that result in the cessation of further infusions'}, {'measure': 'Area under the curve for corticosteroids', 'timeFrame': '180 days', 'description': 'To measure the corticosteroid dose and to compare the corticosteroid sparing effect of rituximab versus conventional therapy'}, {'measure': 'Area under the curve for corticosteroids', 'timeFrame': '360 days', 'description': 'To measure the corticosteroid dose and to compare the corticosteroid sparing effect of rituximab versus conventional therapy'}, {'measure': 'Number of sequelae assessed by the Vasculitis Damage Index', 'timeFrame': '180 days'}, {'measure': 'Number of sequelae assessed by the Vasculitis Damage Index', 'timeFrame': 'day 180 and day 360'}, {'measure': 'ANCA titers and CD19+cells', 'timeFrame': 'day 180 and day 360'}, {'measure': 'Health Assessment Questionnaire (HAQ) score', 'timeFrame': '180 days', 'description': 'to evaluate functional disability'}, {'measure': 'Health Assessment Questionnaire (HAQ) score', 'timeFrame': '360 days', 'description': 'to evaluate functional disability'}, {'measure': 'Short Form-36 score', 'timeFrame': '180 days', 'description': 'to evaluate quality of life'}, {'measure': 'Short Form-36 score', 'timeFrame': '360 days', 'description': 'to evaluate quality of life'}]}, 'oversightModule': {'oversightHasDmc': False}, 'conditionsModule': {'keywords': ['Rituximab', 'remission induction', 'eosinophilic granulomatosis with polyangiitis'], 'conditions': ['Eosinophilic Granulomatosis With Polyangiitis (EGPA)']}, 'referencesModule': {'references': [{'pmid': '40720835', 'type': 'DERIVED', 'citation': 'Terrier B, Pugnet G, de Moreuil C, Bonnotte B, Benhamou Y, Chauveau D, Besse MC, Duffau P, Limal N, Neel A, Urbanski G, Jourde-Chiche N, Martin-Silva N, Campagne J, Mekinian A, Schleinitz N, Ackermann F, Fauchais AL, Froissart A, Le Gallou T, Uzunhan Y, Viallard JF, Berezne A, Chiche L, Taille C, Direz G, Durel CA, Godmer P, Trad S, Lambert M, de Menthon M, Quemeneur T, Cadranel J, Charles P, Dossier A, Jilet L, Guillevin L, Abdoul H, Puechal X; French Vasculitis Study Group. Rituximab Versus Conventional Therapy for Remission Induction in Eosinophilic Granulomatosis With Polyangiitis : A Randomized Controlled Trial. Ann Intern Med. 2025 Sep;178(9):1249-1257. doi: 10.7326/ANNALS-24-03947. Epub 2025 Jul 29.'}], 'seeAlsoLinks': [{'url': 'http://www.vascularites.org/', 'label': 'Related Info'}]}, 'descriptionModule': {'briefSummary': 'Phase III, comparative, multicenter, randomized, controlled, double-blind and superiority research, comparing rituximab-based regimen with conventional therapeutic strategy for the induction of remission in patients with eosinophilic granulomatosis with polyangiitis (EGPA).\n\nPatients with newly diagnosed or relapsing EGPA will be randomized in a 1:1 ratio to receive:\n\n* Experimental therapeutic strategy based on the use of rituximab (experimental group)\n* Conventional therapeutic strategy based on Five-Factor Score (FFS)-assessed disease severity (comparative group)', 'detailedDescription': 'Systemic vasculitides are inflammatory diseases of blood vessels, among which anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAV) are often severe with life-threatening manifestations or complications. AAV include granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA) and eosinophilic granulomatosis with polyangiitis (EGPA, formerly Churg-Strauss syndrome).\n\nCytotoxic drugs and glucocorticoids have been the standard of care for remission induction for nearly five decades. This regimen improved the outcome of severe AAV from death to a strong likelihood of disease control and temporary remission. However, a remission is not obtained in all patients with this combination of drugs, and most patients experience disease flares requiring repeated treatment with associated significant morbidity and mortality.\n\nIn 2 prospective controlled trials, rituximab, an anti-CD20 monoclonal antibody, was shown to be non inferior to cyclophosphamide to induce remission with an acceptable safety profile in patients with systemic GPA and MPA. However, patients with EGPA were not included in these trials and rituximab has not been evaluated prospectively to induce remission in this disease which pathogenesis is complex and not only restricted to ANCA responsibility.\n\nIn patients with EGPA, overall survival is good when treatment is stratified according to prognostic factors (Five Factor Score) but long-term outcome is not so good since relapses occur in more than 40% of patients, leading to high cumulative morbidity and damage. In small retrospective studies, rituximab seems promising as a remission-induction agent in patients with EGPA, independently from the ANCA status.\n\nThe trial detailed here is the first prospective trial evaluating rituximab as induction-remission treatment for EGPA.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Patients with a diagnosis of EGPA independently of ANCA status,\n* Patient aged of 18 years or older,\n* Patients with newly-diagnosed disease or relapsing disease at the time of screening, with an active disease defined as a Birmingham Vasculitis Activity Score (BVAS) ≥3,\n* Patients within the first 21 days following initiation/increase of corticosteroids at a dose ≤ 1 mg/kg/day (pulses of methylprednisolone before oral corticosteroid therapy are authorized) ,\n* Patient able to give written informed consent prior to participation in the study.\n\nExclusion Criteria:\n\n* Patients with GPA, MPA, or other vasculitides, defined by the ACR criteria and/or the Chapel Hill Consensus Conference,\n* Patients with vasculitis in remission of the disease defined as a BVAS \\<3,\n* Patients with severe cardiac failure defined as class IV in New York Heart Assocation\n* Patients with acute infections or chronic active infections (including HIV, HBV or HCV),\n* Patients with active cancer or recent cancer (\\<5 years), except basocellular carcinoma and prostatic cancer of low activity controlled by hormonal treatment,\n* Pregnant women and lactation. Patients with childbearing potential should have reliable contraception for the 12 months duration of the study,\n* Patients with EGPA who have already been treated with rituximab within the previous 12 months,\n* Patients with hypersensitivity to a monoclonal antibody or biologic agent,\n* Patients with contraindication to use rituximab, cyclophosphamide, mesna or azathioprine,\n* Patients with other uncontrolled diseases, including drug or alcohol abuse, severe psychiatric diseases, that could interfere with participation in the trial according to the protocol,\n* Patients included in other investigational therapeutic study within the previous 3 months,\n* Patients suspected not to be observant to the proposed treatments,\n* Patients who have white blood cell count ≤4,000/mm3,\n* Patients who have platelet count ≤100,000/mm3,\n* Patients who have ALT or AST level greater that 3 times the upper limit of normal that cannot be attributed to underlying EGPA disease,\n* Patients unable to give written informed consent prior to participation in the study.'}, 'identificationModule': {'nctId': 'NCT02807103', 'acronym': 'REOVAS', 'briefTitle': 'Rituximab in Eosinophilic Granulomatosis With Polyangiitis', 'organization': {'class': 'OTHER', 'fullName': 'Assistance Publique - Hôpitaux de Paris'}, 'officialTitle': 'Evaluation of Rituximab-based Regimen Compared to Conventional Therapeutic Strategy For Remission Induction In Patients With Newly-Diagnosed or Relapsing Eosinophilic Granulomatosis With Polyangiitis. Prospective, Randomized, Controlled, Double-blind Study', 'orgStudyIdInfo': {'id': 'P140915'}, 'secondaryIdInfos': [{'id': '2016-000275-25', 'type': 'EUDRACT_NUMBER'}]}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Rituximab with FFS=0', 'description': 'All patients in the rituximab group will receive corticosteroids with a predefined tapering schedule similar to the conventional therapy group.\n\nPatients with FFS=0 will receive 1 gram of rituximab at day 1 and day 15 as induction treatment', 'interventionNames': ['Drug: Rituximab']}, {'type': 'PLACEBO_COMPARATOR', 'label': 'Conventional therapy with FFS=0', 'description': 'All patients will receive corticosteroids with a predefined tapering schedule similar to the experimental group.\n\nPatients with FFS=0 will receive placebo-rituximab at day 1 and day 15.', 'interventionNames': ['Drug: Placebo-rituximab']}, {'type': 'EXPERIMENTAL', 'label': 'Rituximab with FFS≥1', 'description': 'All patients in the rituximab group will receive corticosteroids with a predefined tapering schedule similar to the conventional therapy group.\n\nPatients with FFS≥1 will receive a total of 9 pulses :\n\n* 1 gram of rituximab at day 1 and day 15 as induction treatment\n* placebo-cyclophosphamide at days 1, 15, 29, 50, 71, 92, 113, 134 and 155.\n\nMaintenance therapy by azathioprine will be started at day 180 according to the standard of care of these patients, as recommended by the French Vasculitis Study Group.', 'interventionNames': ['Drug: Rituximab', 'Drug: Placebo-cyclophosphamide']}, {'type': 'ACTIVE_COMPARATOR', 'label': 'Conventional therapy with FFS≥1', 'description': 'All patients will receive corticosteroids with a predefined tapering schedule similar to the experimental group.\n\nPatients with FFS≥1 will receive intravenous pulses of cyclophosphamide for a total of 9 pulses: 600 mg/m2 at days 1, 15 and 29, and then 500 mg-fixed dose at days 50, 71, 92, 113, 134 and 155.\n\nMaintenance therapy by azathioprine will be started at day 180 according to the standard of care of these patients, as recommended by the French Vasculitis Study Group.', 'interventionNames': ['Drug: Cyclophosphamide']}], 'interventions': [{'name': 'Rituximab', 'type': 'DRUG', 'otherNames': ['Mabthera'], 'description': '1 g intravenous pulse at day1 and day15', 'armGroupLabels': ['Rituximab with FFS=0', 'Rituximab with FFS≥1']}, {'name': 'Placebo-rituximab', 'type': 'DRUG', 'otherNames': ['nacl'], 'description': 'intravenous pulses at day1 and day15', 'armGroupLabels': ['Conventional therapy with FFS=0']}, {'name': 'Cyclophosphamide', 'type': 'DRUG', 'otherNames': ['endoxan'], 'description': 'intravenous 9 pulses : 600 mg/m2 at days 1, 15 and 29, and then 500 mg-fixed dose at days 50, 71, 92, 113, 134 and 155.', 'armGroupLabels': ['Conventional therapy with FFS≥1']}, {'name': 'Placebo-cyclophosphamide', 'type': 'DRUG', 'otherNames': ['Nacl'], 'description': 'intravenous 7 pulses : at days 29, 50, 71, 92, 113, 134 and 155.', 'armGroupLabels': ['Rituximab with FFS≥1']}]}, 'contactsLocationsModule': {'locations': [{'zip': '75014', 'city': 'Paris', 'country': 'France', 'facility': 'Hôpital Cochin', 'geoPoint': {'lat': 48.85341, 'lon': 2.3488}}], 'overallOfficials': [{'name': 'Xavier PUECHAL, MD, PhD', 'role': 'STUDY_CHAIR', 'affiliation': 'Centre de référence " Maladies systémiques et autoimmunes rares, en particulier Vascularites nécrosantes et Sclérodermies systémiques "'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Assistance Publique - Hôpitaux de Paris', 'class': 'OTHER'}, 'collaborators': [{'name': 'French Vasculitis Study Group', 'class': 'OTHER'}], 'responsibleParty': {'type': 'SPONSOR'}}}}